Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Tackenberg

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 25, 2001
Immunosuppressive treatment of ocular myasthenia gravisB Tackenberg, B Hemmer, W H Oertel, et al.
Der Internist|March 23, 2016
[Myasthenia gravis]J Schodrowski, M Seipelt, I Adibi-Sedeh, et al.
MMW Fortschritte Der Medizin|August 30, 2007
[Advances in the treatment of multiple sclerosis?]B Tackenberg, H Himmerich, A Wellek, et al.
MMW Fortschritte Der Medizin|August 6, 2008
[Myasthenia gravis--diagnosis, therapy and special problems]B Tackenberg, K Gellert, J Kruth, et al.
Der Nervenarzt|September 26, 2014
[Prognostic and predictively relevant factors for multiple sclerosis]B Tackenberg, T Schneider-Hohendorf, A Müller, et al.
Der Nervenarzt|April 3, 2015
[Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis]V I Leussink, C Warnke, B Tackenberg, et al.
Peptides|March 11, 1998
Effects of VIP and related peptides on airway mucus secretion from isolated rat tracheaU Wagner, D Bredenbröker, B Storm, et al.
Journal of Neuroimmunology|September 29, 2009
Expanded TCR Vbeta subsets of CD8(+) T-cells in late-onset myasthenia gravis: novel parallels with thymoma patientsB Tackenberg, K Schlegel, M Happel, et al.
European Journal of Neurology|May 20, 2008
Immunophenotyping in Tourette syndrome--a pilot studyJ C Möller, B Tackenberg, M Heinzel-Gutenbrunner, et al.
Autoimmunity|June 25, 2003
CD45 isoform expression in autoimmune myasthenia gravisB Tackenberg, M Nitschke, N Willcox, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 25, 2001
Immunosuppressive treatment of ocular myasthenia gravisB Tackenberg, B Hemmer, W H Oertel, et al.
Der Internist|March 23, 2016
[Myasthenia gravis]J Schodrowski, M Seipelt, I Adibi-Sedeh, et al.
MMW Fortschritte Der Medizin|August 30, 2007
[Advances in the treatment of multiple sclerosis?]B Tackenberg, H Himmerich, A Wellek, et al.
MMW Fortschritte Der Medizin|August 6, 2008
[Myasthenia gravis--diagnosis, therapy and special problems]B Tackenberg, K Gellert, J Kruth, et al.
Der Nervenarzt|September 26, 2014
[Prognostic and predictively relevant factors for multiple sclerosis]B Tackenberg, T Schneider-Hohendorf, A Müller, et al.
Der Nervenarzt|April 3, 2015
[Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis]V I Leussink, C Warnke, B Tackenberg, et al.
Peptides|March 11, 1998
Effects of VIP and related peptides on airway mucus secretion from isolated rat tracheaU Wagner, D Bredenbröker, B Storm, et al.
Journal of Neuroimmunology|September 29, 2009
Expanded TCR Vbeta subsets of CD8(+) T-cells in late-onset myasthenia gravis: novel parallels with thymoma patientsB Tackenberg, K Schlegel, M Happel, et al.
European Journal of Neurology|May 20, 2008
Immunophenotyping in Tourette syndrome--a pilot studyJ C Möller, B Tackenberg, M Heinzel-Gutenbrunner, et al.
Autoimmunity|June 25, 2003
CD45 isoform expression in autoimmune myasthenia gravisB Tackenberg, M Nitschke, N Willcox, et al.
Pageof 2